TriSalus Life Sciences, Inc.: insider trades · United States · SEC (Form 4)

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is a U.S.-listed oncology-focused medical technology company traded on the Nasdaq under the ticker TLSI. Its corporate headquarters are in Westminster, Colorado, United States. The company sits at the intersection of interventional medical devices and oncology drug development, with a strategy aimed at improving how therapies are delivered into solid tumors, especially in the liver and pancreas. TriSalus’ current public-company structure dates to the August 10, 2023 merger with a SPAC, but its operating heritage predates that transaction and reflects years of development around its proprietary delivery platform. Under the leadership of Mary Szela, the company has built its equity story around Pressure-Enabled Drug Delivery, or PEDD, a patented approach designed to overcome the anatomical barriers that can make conventional infusion less effective in solid tumors. TriSalus currently markets two FDA-cleared device platforms: the TriNav Infusion System, used for hepatic arterial infusion of liver tumors and other solid tumors, and the Pancreatic Retrograde Venous Infusion System, which is designed for pancreatic tumors. In practical terms, these systems are intended to increase therapeutic delivery to tumor tissue while limiting exposure to normal tissue, which is the key clinical rationale behind the platform. In addition to its device business, TriSalus is developing nelitolimod, an investigational immunotherapy candidate intended to address the immunosuppressive tumor microenvironment that can blunt responses to current therapies, particularly in the liver and pancreas. From a commercial standpoint, the company has recently shown improving momentum. In January 2026, TriSalus reported preliminary full-year 2025 revenue of approximately $45.2 million, up sharply year over year, and set initial 2026 revenue guidance of approximately $60 million to $62 million. The company also noted continued adoption of the TriNav product suite across a broader range of solid tumor indications. During 2025, TriSalus expanded its portfolio with the commercial launch of the TriNav FLX Infusion System and the TriNav XP Infusion System, broadening the TriNav family and strengthening its competitive position in interventional oncology. The business is primarily U.S.-based, with operations and facilities in Westminster, Colorado, as well as additional offices in Illinois and Rhode Island. For investors, TriSalus remains a growth-oriented, clinically driven medtech name whose market opportunity depends on adoption of its proprietary delivery technology, continued product expansion, and execution in a specialized oncology niche.